InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.730 0.03 (4.29%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$348 Starpharma to present at OTCQX Life Sciences Investor Forum 17 Sep 2020 8:49AM $1.670 $0.730 fallen by 56.29%
$348 Change in substantial holding 17 Sep 2020 8:17AM $1.670 $0.730 fallen by 56.29%
$348 SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2 14 Sep 2020 11:10AM $1.575 $0.730 fallen by 53.65%
$348 Change in substantial holding 3 Sep 2020 5:34PM $1.700 $0.730 fallen by 57.06%
$348 Starpharma awarded $1M MRFF funding for COVID-19 spray 3 Sep 2020 9:24AM $1.630 $0.730 fallen by 55.21%
$348 SPL creates slow release soluble DEP remdesivir nanoparticle 1 Sep 2020 9:01AM $1.515 $0.730 fallen by 51.82%
$348 Change in substantial holding 1 Sep 2020 8:05AM $1.515 $0.730 fallen by 51.82%
$348 Appendix 4G - Corporate Governance Statement 27 Aug 2020 9:33AM $1.330 $0.730 fallen by 45.11%
$348 Starpharma annual report and full year financial results 27 Aug 2020 9:22AM $1.330 $0.730 fallen by 45.11%
$348 SPL7013 nasal spray for COVID19 development update 25 Aug 2020 9:50AM $1.050 $0.730 fallen by 30.48%
$348 Starpharma signs new DEP partnership with Chase Sun 17 Aug 2020 8:59AM $1.030 $0.730 fallen by 29.13%
$348 Quarterly Cashflow and Activities Report 30 Jul 2020 11:31AM $1.105 $0.730 fallen by 33.94%
$348 DEP docetaxel and gemcitabine combination trial commences 30 Jul 2020 10:58AM $1.125 $0.730 fallen by 35.11%
$348 AZD0466 trial opens MD Anderson Cancer Center as a site 27 Jul 2020 9:12AM $1.170 $0.730 fallen by 37.61%
$348 New Australian site opening for DEP trials 9 Jul 2020 9:06AM $1.180 $0.730 fallen by 38.14%
$348 DEP irinotecan boosts immuno-oncology in colon cancer models 29 Jun 2020 9:16AM $1.165 $0.730 fallen by 37.34%
$348 DEP products showcased at AACR 2020 23 Jun 2020 9:06AM $1.115 $0.730 fallen by 34.53%
$348 Starpharma to present at OTCQX Virtual Investor Conference 18 Jun 2020 1:02PM $1.060 $0.730 fallen by 31.13%
$348 DEP lutetium effective in human prostate cancer model 17 Jun 2020 10:06AM $1.055 $0.730 fallen by 30.81%
$348 VivaGel BV launched in central and eastern Europe 16 Jun 2020 10:05AM $0.970 $0.730 fallen by 24.74%
$348 Becoming a substantial holder 15 Jun 2020 7:30PM $0.970 $0.730 fallen by 24.74%
$348 Becoming a substantial holder 26 May 2020 8:19AM $1.135 $0.730 fallen by 35.68%
$348 Shareholder Update May 2020 14 May 2020 11:34AM $0.983 $0.730 fallen by 25.70%
$348 DEP irinotecan phase 2 commences after positive phase 1 7 May 2020 9:42AM $0.960 $0.730 fallen by 23.96%
$348 Starpharma presents at Macquarie Australia Conference 5 May 2020 9:30AM $1.000 $0.730 fallen by 27%

376 - 400 of 875 results

Page 16 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.